With effect from January 1, 2026, the diabetic medication Galvus and its combination brands will be manufactured and marketed by the pharmaceutical company Cipla under a perpetual licencing arrangement with Novartis Pharma AG (Switzerland).   

Galvus, one of the top brands in the Dipeptidyl Peptidase-4 (DPP4) market, particularly in oral diabetic treatment, has the potential to make a major contribution to its portfolio, as per Cipla.